Evidence map›Paper›PMID 40583882›Full record

ArticleBasic and clinical neuroscience

Association of

Abdollah Golnezhad, Anahita Torkaman-Boutorabi, Emran Mohammad Razaghi, Mohammad Reza Zarrindast, Mohammad Reza Mahdavi, Nasim Vousooghi

Abstract read
In one paragraph

Article in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdollah GolnezhadDepartment of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0009-0009-9036-2892
Anahita Torkaman-BoutorabiDepartment of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-2045-7668
Emran Mohammad RazaghiDepartment of Psychiatry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-9640-981X
Mohammad Reza ZarrindastDepartment of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-0688-5378
Mohammad Reza MahdaviThalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-1453-5570
Nasim VousooghiResearch Center for Cognitive and Behavioral Sciences, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-3392-3640

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Treatment of opioid use disorders (OUDs) via safe and effective approaches has been investigated for years. Methadone maintenance treatment (MMT) has been considered an effective therapy for opioid addiction. It has been observed that patients with genetic polymorphisms often show variability in the optimal drug dose requirement and treatment schedule. This study aimed to investigate the relationship between single nucleotide polymorphisms (SNPs) in the ATP-binding cassette subfamily B member-1 ( Methods: In a cross-sectional study, 216 male MMT patients (20 to 45 years old) who were involved in the treatment program for at least three months were randomly recruited from six MMT clinics in Mazandaran province between 2018 and 2020. Blood samples were taken, DNA was extracted, and SNPs of Results: Our results showed no significant relationship between all the studied genotypes and methadone dose requirements. Conclusion: The present study, for the first time in the Mazandaran population, reported no significant correlations between methadone dose requirement and different SNPs in the

Indexed as

ABCB1AddictionCYPIranMethadone maintenanceOPRM1Polymerase chain reaction-restriction fragment length polymorphism (RFLP)

Identifiers

PMID40583882
PMCPMC12198743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.